<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119639</url>
  </required_header>
  <id_info>
    <org_study_id>11804</org_study_id>
    <nct_id>NCT00119639</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006</brief_title>
  <official_title>A Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of Sorafenib (BAY 43-9006, Nexavar).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      This is a 400 mg (2 x 200 mg tablets) sorafenib single dose, open-label study being conducted
      to compare the pharmacokinetics of plasma and urine and safety of sorafenib in subjects with
      severe, moderate, and mild renal impairment with those exhibiting normal renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of sorafenib in plasma and urine; single-dose safety of sorafenib in patients with renal impairment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (BAY43-9006, Nexavar)</intervention_name>
    <description>All subjects were given a open-label, single dose of 400mg sorafenib</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post menopausal females

          -  Surgically sterile females

          -  Body Mass Index between 18-37

          -  Subjects with Clcr greater than 80 mL/min

          -  Subjects with Clcr 50 to 80 mL/min

          -  Subjects with Clcr 30 to 50 mL/min

          -  Clcr less than 30 mL/min but not on dialysis

          -  Subjects must test negative for HIV

          -  Subjects must test negative for drugs of abuse at screening

        Exclusion Criteria:

        All Subjects :

          -  Concomitant Medication: Treatment with CYP3A4 inducers, such as rifampin and St.
             John's Wort within 14 days of Day 1 until they leave the clinic on Day 7

          -  Donation of blood within 30 days of Day 1

          -  Recent participation in an investigational drug study during which active medication
             was given within 30 days of Day 1

          -  History of gastrointestinal disorder that could result in incomplete absorption of
             study drug

          -  Malignancy

          -  Significant neurologic or psychiatric disorders

          -  History of drug or alcohol abuse in year prior to screening for this trial, or current
             intake or &gt;14 standard alcoholic drinks per week

          -  Prior history of epilepsy or other seizure disorders

          -  Known hypersensitivity to inhibitors of raf kinase or VEGFR-2

          -  Females of child-bearing potential

          -  Smoking &gt; 10 cigarettes/day or equivalent

          -  Excessive consumption (more than five 8-oz. cups/day) of coffee or caffeine

        Healthy Volunteer:

          -  Existing failure of a major organ system, or a medical disorder that would impair the
             subject's ability to complete the study (in the opinion of the investigator or the
             sponsor), eg history of blood coagulation disorders

          -  Hematocrit value &lt; 34% in the control group at screening

        Renal Impairment Groups:

          -  Existing failure of a major organ system or a medical disorder (other than the target
             disease) which would impair the subject's ability to complete the study (in the
             opinion of the investigator or the sponsor)

          -  Concomitant Medication: Renal impairment subjects taking phosphate binders, ion
             exchange resins and/or iron supplements may take them with their meals, but must
             withhold them on the morning of Day 1 (dosing day) until after their 4 hour post-dose
             tests and procedures are performed.

          -  Myocardial infarction, coronary artery bypass graft or percutaneous transluminal
             coronary angiography within 6 months of Day 1; unstable angina; uncontrolled
             significant hypertension within 3 months of Day 1; cerebral vascular accident or
             transient ischemic attack within 12 months of Day 1

          -  Subjects with hypertension who have had a medication or dose change within one week of
             Day 1

          -  Subjects requiring dialysis

          -  Subjects with kidney transplants

          -  Liver transaminase (AST, ALT) greater than 5 times the ULN at screening; any active
             liver disease or unexplained or persistent elevations in liver function tests

          -  Hematocrit value &lt; 24% in the renal impaired groups
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2005</study_first_posted>
  <last_update_submitted>January 15, 2009</last_update_submitted>
  <last_update_submitted_qc>January 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Pharmacology</name_title>
    <organization>Bayer Healthcare Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

